SGLT2 inhibitors as the bedrock of therapy for heart failure

Lancet. 2022 Sep 3;400(10354):711-713. doi: 10.1016/S0140-6736(22)01584-7. Epub 2022 Aug 27.
No abstract available

Publication types

  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Heart Failure* / drug therapy
  • Humans
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors